Orbimed Advisors Llc - Apr 10, 2025 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)

Role
10%+ Owner
Signature
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Stock symbol
XTNT
Transactions as of
Apr 10, 2025
Transactions value $
-$30,708,129
Form type
4
Date filed
4/14/2025, 07:14 PM
Previous filing
Apr 11, 2025
Next filing
Apr 17, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XTNT Common Stock Sale -$23.5M -56M -100% $0.42 0 Apr 10, 2025 See footnotes F1, F3
transaction XTNT Common Stock Sale -$7.19M -17.1M -100% $0.42 0 Apr 10, 2025 See footnotes F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Orbimed Advisors Llc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. By virtue of such relationships, OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.
F2 These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II, and OrbiMed Advisors is the managing member of ROF II. By virtue of such relationships, ROF II and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by ORO II.
F3 This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.